Mingde Biotech announced that on December 29, 2025, the company signed an “Share Acquisition Intent Agreement” with Lanfan Medical to acquire 100% of its shares in Wuhan Biker Rescue Products Co., Ltd. in cash, which is expected to constitute a major asset restructuring. The transaction is still in the planning stage, and the final transaction consideration for the underlying asset will be determined through negotiation based on the assessed value. This acquisition is an important layout for the company to focus on critical business, and can build a collaborative ecosystem. However, the transaction is uncertain, including unknown results such as due diligence and approval, and may also face operational and integration risks.

Mingde Biotech announced that on December 29, 2025, the company signed an “Share Acquisition Intent Agreement” with Lanfan Medical to acquire 100% of its shares in Wuhan Biker Rescue Products Co., Ltd. in cash, which is expected to constitute a major asset restructuring. The transaction is still in the planning stage, and the final transaction consideration for the underlying asset will be determined through negotiation based on the assessed value. This acquisition is an important layout for the company to focus on critical business, and can build a collaborative ecosystem. However, the transaction is uncertain, including unknown results such as due diligence and approval, and may also face operational and integration risks.